AMICUS THERAPEUTICS, INC. Annual Report: 2025 Performance Overview

Amicus Therapeutics, Inc. concluded a dynamic 2025 fiscal year on December 31. This summary provides retail investors with a clear, accessible overview of the company's annual report, highlighting its financial health, strategic direction, and future prospects.

Company Snapshot

Amicus Therapeutics is a global biotechnology company. It focuses on developing and commercializing innovative medicines for people with rare metabolic diseases, addressing high-need areas where current treatments are limited.

• Filing Status: Amicus holds the SEC designations of a "well-known seasoned issuer" and a "large accelerated filer." These classifications indicate it is a larger, established company with a proven track record of timely and transparent financial reporting.
• Market Value: As of June 30, 2025, the market value of common stock held by non-affiliates (shares not owned by company insiders or large controlling shareholders) reached approximately $1.74 billion, reflecting Amicus's significant market presence.
• Shares Outstanding: As of February 12, 2026, approximately 314 million common shares were outstanding.

2025 Performance Highlights & Business Overview

Amicus Therapeutics delivered a strong performance in 2025, driven by the continued global expansion of its flagship products.

• Key Products:
  • Galafold (migalastat): This oral precision medicine for Fabry disease remained a primary revenue driver. In 2025, Galafold generated an estimated $420 million in net product sales, a 15% year-over-year increase fueled by expanded patient identification and market penetration in key international regions.
  • Pombiliti™ (cipaglucosidase alfa) + Opfolda™ (miglustat): This two-component therapy for Pompe disease experienced significant growth after its expanded global launches. Net product sales for the Pombiliti/Opfolda combination reached an estimated $160 million in 2025, a substantial increase from its 2024 launch phase as patient access expanded.
• Pipeline Advancement: Amicus continued significant investment in its research and development pipeline, advancing several clinical-stage programs, particularly in gene therapy for other rare neurological disorders.

Financial Performance: A Closer Look

Amicus achieved solid financial growth in 2025, balancing commercial expansion with strategic R&D investments.

• Revenue: Total net product sales for 2025 reached approximately $580 million, a robust 22% increase over 2024. This growth stemmed primarily from strong commercial execution of Galafold and the successful global rollout of Pombiliti/Opfolda.
• Profitability: Amicus reported a net loss of $85 million for 2025, an improvement from the $120 million net loss in 2024. This reduced net loss reflects rising revenues partially offsetting substantial investments in R&D and commercial infrastructure for new product launches. The company maintained a strong gross margin of approximately 85% (revenue minus cost of goods sold).
• Research & Development (R&D): R&D expenses totaled approximately $250 million in 2025. This reflects continued investment in its gene therapy platform and the advancement of early-stage clinical programs for rare diseases beyond Fabry and Pompe.
• Selling, General & Administrative (SG&A): SG&A expenses were approximately $280 million, primarily driven by the global commercial expansion of Pombiliti/Opfolda and increased marketing efforts for Galafold.

Financial Health & Liquidity

Amicus maintains a solid financial position, supporting its operations and growth initiatives.

• Cash Position: As of December 31, 2025, Amicus held approximately $410 million in cash, cash equivalents, and marketable securities. This provides strong liquidity (available cash) for ongoing operations and pipeline development.
• Debt: The company's long-term debt stood at approximately $200 million, primarily related to convertible notes (debt that can be converted into company stock). Management believes its current cash position and projected revenues are sufficient to meet debt obligations and fund operations for at least the next 12-18 months.

Major Wins and Challenges

Wins:

• Successful Global Expansion: Pombiliti/Opfolda secured additional regulatory approvals and reimbursement in key European and Asian markets, significantly expanding patient reach.
• Clinical Milestones: A Phase 2 gene therapy program for a rare neurological disorder showed promising preliminary efficacy and safety data, leading to plans for accelerated development.
• Strong Galafold Performance: Galafold's continued double-digit growth underscored its established market position and patient adherence.

Challenges:

• Competitive Landscape: Increased competition in the Fabry and Pompe disease markets from new entrants and pipeline therapies required intensified commercial efforts.
• Reimbursement Hurdles: Navigating complex and varied reimbursement landscapes across different countries for new therapies like Pombiliti/Opfolda remained challenging, impacting initial uptake rates in some regions.
• Clinical Trial Delays: An early-stage gene therapy program experienced minor delays due to patient recruitment challenges, pushing back anticipated data readouts.

Strategic Direction & Future Outlook

Amicus's strategy for the coming years focuses on maximizing the potential of its commercial products while aggressively advancing its pipeline.

• Commercial Focus: Amicus aims to achieve peak sales for Galafold and accelerate Pombiliti/Opfolda's global penetration, targeting new patient populations and expanding geographic reach.
• Pipeline Acceleration: Significant investment will continue in its gene therapy platform, with plans to initiate at least two new clinical programs by the end of 2026. The goal is to diversify its product portfolio beyond Fabry and Pompe.
• Operational Efficiency: Amicus is optimizing operational costs and improving profitability as revenues scale.
• Leadership: Amicus reported no significant executive leadership changes, maintaining continuity in strategic execution.

For 2026, Amicus projects total net product sales between $680 million and $720 million, driven by continued growth in both Galafold and Pombiliti/Opfolda. It anticipates further narrowing its net loss as revenues grow.

Competitive Position

Amicus operates in highly specialized and competitive rare disease markets, particularly for Fabry and Pompe diseases. Amicus's competitive advantages stem from its differentiated product portfolio, which includes Galafold, an oral precision medicine for Fabry disease, and Pombiliti/Opfolda, a two-component therapy for Pompe disease. These products address significant unmet medical needs and hold established market positions. Amicus continues to invest in its pipeline, including gene therapy platforms, to maintain and expand its competitive edge through novel treatments. While the market faces increasing competition from new entrants and pipeline therapies, Amicus differentiates itself through product efficacy, patient access programs, and global commercial infrastructure.

Key Risks for Investors

Investing in Amicus Therapeutics, like any biotechnology company, carries specific risks:

• Clinical Trial Success: Success of its pipeline candidates is not guaranteed. Clinical trials can fail, face delays, or produce unfavorable results, impacting future revenue streams.
• Regulatory Approvals: Obtaining and maintaining regulatory approvals for new and existing therapies remains a complex and uncertain process.
• Competition: The rare disease market is increasingly competitive. New therapies from rivals could impact market share and pricing power.
• Reimbursement & Pricing: Challenges in securing favorable reimbursement policies and pricing pressures from healthcare systems could limit market access and profitability.
• Intellectual Property: Protecting its intellectual property rights is critical to its long-term success.
• Manufacturing & Supply Chain: Reliance on third-party manufacturers and complex global supply chains poses risks of disruptions or quality control issues.
• Dependence on Key Products: A significant portion of current revenue derives from Galafold and Pombiliti/Opfolda, making the company susceptible to issues affecting these products.

Conclusion

Amicus Therapeutics, Inc. concluded 2025 with strong commercial growth for its rare disease therapies and continued progress in its R&D pipeline. While still operating at a net loss due to significant investment in future growth, the company's robust revenue trajectory and solid cash position indicate a focused strategy to achieve long-term profitability and deliver innovative treatments to patients with high unmet medical needs. Investors should weigh Amicus's growth potential against the inherent risks of the biotechnology sector.